PRESS RELEASES

PRESS RELEASES

Date Title and Summary Additional Formats
Toggle Summary Versartis Presents 3-Year Somavaratan Safety and Efficacy Data and Pediatric Program Baseline Demographics at the 19th European Congress of Endocrinology
MENLO PARK, Calif., May 22, 2017 (GLOBE NEWSWIRE) -- Versartis, Inc. (NASDAQ:VSAR), an endocrine-focused biopharmaceutical company that is developing somavaratan, a novel, long-acting form of recombinant human growth hormone (rhGH) for growth hormone deficiency (GHD), announced that three-year
View HTML
Toggle Summary Versartis Reports First Quarter 2017 Financial Results
MENLO PARK, Calif., April 27, 2017 (GLOBE NEWSWIRE) -- Versartis, Inc. (NASDAQ:VSAR), an endocrine-focused biopharmaceutical company that is developing somavaratan, a novel, long-acting form of recombinant human growth hormone (rhGH) for growth hormone deficiency (GHD), today announced financial
View HTML
Toggle Summary Versartis Appoints Jay Stout, Ph.D., as Senior Vice President, Technical Operations
MENLO PARK, Calif., April 25, 2017 (GLOBE NEWSWIRE) -- Versartis, Inc. (NASDAQ:VSAR), an endocrine-focused biopharmaceutical company that is developing somavaratan, a novel, long-acting form of recombinant human growth hormone (rhGH) for growth hormone deficiency (GHD), today announced the
View HTML
Toggle Summary Versartis Announces Three Year Somavaratan Data at ENDO 2017 Showing Safety and Efficacy in Line with Historical U.S. Daily rhGH Data in Pediatric GHD
- Mean height velocity during Years 1, 2, and 3 remained consistent and in line with U.S. daily rhGH treatment- Height-SDS during the three-year treatment period continued to improve from baseline and was in line with U.S. registry data- IGF-I responses achieved the target therapeutic range and were similar to U.S. registry data
View HTML
Toggle Summary Versartis Reports New Data on Long-Acting Somavaratan in Growth Hormone Deficiency at ENDO 2017
- Baseline characteristics of Phase 3 VELOCITY trial population balanced between study arms and comparable to Phase 2- Further results from the VITAL trial in adult GHD- Similar somavaratan PK/PD data in U.S. and Japanese children support using the same dose in the ongoing global and Japan Phase 3 trials- Conference call and webcast scheduled for 4:30 pm ET today featuring Versartis management and pediatric endocrinologist Bradley Miller, M.D., Ph.D.
View HTML
Toggle Summary Versartis to Host Conference Call to Review Data from ENDO 2017 on Long-Acting Somavaratan for Growth Hormone Deficiency
Management discussion to include a review of 3-year data from VERTICAL & VISTA Trials Dr. Bradley Miller featured as a guest speaker Conference Call and webcast to be held Monday, April 3 at 4:30pm ET MENLO PARK, Calif., March 23, 2017 (GLOBE NEWSWIRE) -- Versartis, Inc.
View HTML
Toggle Summary Versartis Appoints Tracy Woody as Chief Commercial Officer
MENLO PARK, Calif., March 15, 2017 (GLOBE NEWSWIRE) -- Versartis, Inc. (NASDAQ:VSAR), an endocrine-focused biopharmaceutical company that is developing somavaratan, a novel, long-acting form of recombinant human growth hormone (rhGH) for growth hormone deficiency (GHD), today announced the
View HTML
Toggle Summary Versartis Announces Data on Long-Acting Somavaratan for Growth Hormone Deficiency to be Featured in Late-Breaker Presentation at ENDO 2017
  Similar PK/PD data between US and Japanese children treated with somavaratan support using the same dose in the ongoing US and Japan Phase 3 trials MENLO PARK, Calif., March 02, 2017 (GLOBE NEWSWIRE) -- Versartis, Inc. (NASDAQ:VSAR), an endocrine-focused biopharmaceutical company that is
View HTML
Toggle Summary Versartis to Present at Cowen & Co. Annual Healthcare Conference and Barclays Global Healthcare Conference
MENLO PARK, Calif., March 01, 2017 (GLOBE NEWSWIRE) -- Versartis, Inc. (NASDAQ:VSAR), an endocrine-focused biopharmaceutical company that is developing somavaratan (VRS-317), a novel, long-acting form of recombinant human growth hormone (rhGH) for growth hormone deficiency (GHD), today announced
View HTML
Toggle Summary Versartis Reports Fourth Quarter 2016 Financial Results
MENLO PARK, Calif., Feb. 21, 2017 (GLOBE NEWSWIRE) -- Versartis, Inc. (NASDAQ:VSAR), an endocrine-focused biopharmaceutical company that is developing somavaratan, a novel, long-acting form of recombinant human growth hormone (rhGH) for growth hormone deficiency (GHD), today announced financial
View HTML